Jump to content
  • Sign Up
Celiac.com Sponsor:


Celiac.com Sponsor:

  • Join Our Community!

    Get help in our celiac / gluten-free forum.

  • Jefferson Adams
    Jefferson Adams

    Mayo Clinic Says New Celiac Drug Reduces GI and Non-GI Symptoms

    Reviewed and edited by a celiac disease expert.

    Caption: Photo: CC--michael hicks

    Celiac.com 07/28/2014 - One angle being tried by researchers to treat celiac disease involves oral peptides. These are orally administered drugs that would prevent an adverse gluten reaction in people with celiac disease who are following a gluten-free diet.

    Photo: CC--michael_hicksThe drugs are intended to prevent adverse reactions from minor gluten contamination or exposure.


    Celiac.com Sponsor:



    In a recent update from the Mayo clinic, Joseph Murray, MD, confirms that larazotide acetate, a first-in-class oral peptide, has ”met the study's primary end point of a reduction in GI symptoms.” Dr. Murray presented the results from the study as a late-breaking abstract at Digestive Disease Week 2014.

    In a celiac disease reaction, the epithelial tight junctions that control paracellular permeability are compromised, and gut permeability increases. This is partly due to an inflammatory immune response to the entrance of gluten peptides into the intestinal lamina propria through these tight junctions.

    Larazotide acetate prevents tight-junction opening and reduces gluten uptake, inhibiting gluten- and cytokine-induced intestinal permeability and inflammation in vivo.

    This randomized, parallel, double-blind, placebo-controlled, multicenter trial was conducted at 74 sites in North America. The aim was to evaluate the effect of larazotide acetate on GI signs and symptoms in patients with celiac disease.

    Source:


    User Feedback

    Recommended Comments

    A waste of research time and money. We need a better solution than this band aid. Put the money to a more specific solution of counteracting the reaction to gluten in the intestine.

    Share this comment


    Link to comment
    Share on other sites
    A waste of research time and money. We need a better solution than this band aid. Put the money to a more specific solution of counteracting the reaction to gluten in the intestine.

    As I read it, this new drug does just that. What is your compliant, exactly?

    Share this comment


    Link to comment
    Share on other sites
    Does anyone know when larazotide acetate will be available for consumer use?

    It's currently in early phase trials. If all goes well the company will apply for FDA approval. Still no time frame beyond early trial information. Stay tuned!

    Share this comment


    Link to comment
    Share on other sites

    I would love to have something that would help take the worry out of cross contamination when eating out but I am hoping that the enzymes that are in clinical trials will do this. I worry about long term problems when we try to modify a normal response. Zonulin causes leaky gut in everyone - in those with celiac disease the junctions are opened for a longer time. I heard Dr. Fasano say that Zonulin is there for a purpose and we don't fully understand it. Is it really safe to inhibit to inhibit this?

    Share this comment


    Link to comment
    Share on other sites
    Guest Tricia M. Hutto, Pharmacist

    Posted

    As I read it, this new drug does just that. What is your compliant, exactly?

    Larazotide does not guard against the long term effect of gluten ingestion for celiac patients. It is designed only to reduce the symptoms that patients experience when they do ingest gluten. This drug is by no means the answer for celiac patients to be able to stop the gluten free diet and not suffer the negative long term effect gluten ingestion will have on the gut.

    Share this comment


    Link to comment
    Share on other sites


    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,000 articles on celiac disease. His coursework includes studies in biology, anatomy, medicine, science, and advanced research, and scientific methods. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

×
×
  • Create New...